Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL

被引：2

作者：

Park, John W. ^{[1
]}

Liu, Minetta C. ^{[2
]}

Yee, Douglas ^{[3
]}

DeMichele, Angela ^{[4
]}

van't Veer, Laura ^{[1
]}

Hylton, Nola ^{[1
]}

Symmans, Fraser ^{[5
]}

Buxton, Meredith B. ^{[1
]}

Chien, A. Jo ^{[1
]}

Wallace, Amy ^{[6
]}

Melisko, Michelle ^{[1
]}

Schwab, Richard ^{[6
]}

Boughey, Judy ^{[2
]}

Tripathy, Debashish ^{[7
]}

Kaplan, Hank ^{[8
]}

Nanda, Rita ^{[9
]}

Chui, Stephen ^{[10
]}

Albain, Kathy S. ^{[11
]}

Moulder, Stacy ^{[5
]}

Elias, Anthony ^{[12
]}

Lang, Julie E. ^{[7
]}

Edminston, Kirsten ^{[13
]}

Northfelt, Donald ^{[14
]}

Euhus, David ^{[15
]}

Khan, Qamar ^{[16
]}

Lyandres, Julia ^{[1
]}

Davis, Sarah E. ^{[1
]}

Yau, Christina ^{[1
]}

Sanil, Ashish ^{[17
]}

Esserman, Laura J. ^{[1
]}

Berry, Donald A. ^{[17
]}

机构：

[1] UCSF, San Francisco, CA USA

[2] Mayo Clin, Rochester, MN USA

[3] Univ Minnesota, Minneapolis, MN USA

[4] Univ Penn, Philadelphia, PA 19104 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Univ Calif San Diego, San Diego, CA 92103 USA

[7] Univ So Calif, Los Angeles, CA USA

[8] Swedish Med Ctr, Seattle, WA USA

[9] Univ Chicago, Chicago, IL 60637 USA

[10] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[11] Loyola Univ, Chicago, IL 60611 USA

[12] Univ Denver, Denver, CO USA

[13] Inova Fairfax Hosp, Falls Church, VA USA

[14] Mayo Clin, Scottsdale, AZ USA

[15] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[16] Univ Kansas, Lawrence, KS 66045 USA

[17] Berry Consultants, Austin, TX USA

来源：

CANCER RESEARCH | 2014年 / 74卷 / 19期

关键词：

D O I：

10.1158/1538-7445.AM2014-CT227

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT227

引用

页数：2

共 50 条

[31] Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer
Wolf, Denise M.
Yau, Christina
Brown-Swigart, Lamorna
Hirst, Gillian
Buxton, Meredith
Paoloni, Melissa
Olopade, Olufunmilayo
De Michele, Angela
Symmans, Fraser
Rugo, Hope
Berry, Don
Esserman, Laura
van't Veer, Laura
[J]. CANCER RESEARCH, 2016, 76
[32] DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer
Wolf, D. M.
Yau, C.
Sanil, A.
Glas, A.
Petricoin, C.
Wulfkuhle, J.
Brown-Swigart, L.
Hirst, G.
Buxton, M.
DeMichele, A.
Hylton, N.
Symmans, F.
Yee, D.
Paoloni, M.
Esserman, L.
Berry, D.
Rugo, H.
Olapade, O.
van't Veer, L.
[J]. CANCER RESEARCH, 2017, 77
[33] Analysis of biomarkers for response and resistance to the AKT inhibitor MK-2206 in the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
Wolf, Denise
Yau, Christina
Brown-Swigart, Lamorna
Hirst, Gillian
Schmidt, Emmett
Townson, Steven
Cristescu, Razvan
Asare, Smita
Berry, Don
Esserman, Laura
van't Veer, Laura
Tripathy, Debu
Chien, Jo
[J]. CANCER RESEARCH, 2018, 78 (04)
[34] PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Stringer-Reasor, Erica
Shatsky, Rebecca A.
Chien, Jo
Wallace, Anne
Boughey, Judy C.
Albain, Kathy S.
Han, Hyo S.
Nanda, Rita
Isaacs, Claudine
Kalinsky, Kevin
Mitri, Zahi
Clark, Amy S.
Vaklavas, Christos
Thomas, Alexandra
Trivedi, Meghna S.
Lu, Janice
Asare, Smita
Lu, Ruixiao
Pitsouni, Maria
Wilson, Amy
Perlmutter, Jane
Rugo, Hope
Schwab, Richard
Symmans, W. Fraser
Hylton, Nola M.
Van 't Veer, Laura
Yee, Douglas
DeMichele, Angela
Berry, Donald
Esserman, Laura J.
[J]. CANCER RESEARCH, 2023, 83 (05)
[35] Application of machine learning to elucidate the biology predicting response in the I-SPY 2 neoadjuvant breast cancer trial
Sayaman, Rosalyn W.
Wolf, Denise M.
Yau, Christina
Wulfkuhle, Julie
Petricoin, Emanuel
Brown-Swigart, Lamorna
Asare, Smita M.
Hirst, Gillian L.
Sit, Laura
O'Grady, Nicholas
Hedistian, Diane
Esserman, Laura J.
LaBarge, Mark A.
van't Veer, Laura J.
[J]. CANCER RESEARCH, 2020, 80 (04)
[36] Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
Yau, Christina
Wolf, Denise
Brown-Swigart, Lamorna
Hirst, Gillian
Sanil, Ashish
Singhrao, Ruby
Asare, Smita
DeMichele, Angela
Berry, Don
Esserman, Laura
van 't Veer, Laura
Nanda, Rita
Liu, Minetta
Yee, Douglas
[J]. CANCER RESEARCH, 2018, 78 (04)
[37] Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Isaacs, Claudine
Nanda, Rita
Chien, Jo
Trivedi, Meghna S.
Stringer-Reasor, Erica
Vaklavas, Christos
Boughey, Judy C.
Sanford, Amy
Wallace, Anne
Clark, Amy S.
Thomas, Alexandra
Albain, Kathy S.
Kennedy, Laura C.
Sanft, Tara B.
Kalinsky, Kevin
Han, Hyo S.
Williams, Nicole
Arora, Mili
Elias, Anthony
Falkson, Carla
Asare, Smita
Lu, Ruixiao
Pitsouni, Maria
Wilson, Amy
Perlmutter, Jane
Rugo, Hope
Schwab, Richard
Symmans, W. Fraser
Hylton, Nola M.
Van't Veer, Laura
Yee, Douglas
DeMichele, Angela
Berry, Donald
Esserman, Laura J.
[J]. CANCER RESEARCH, 2023, 83 (05)
[38] Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Beckwith, Heather
Schwab, Richard
Yau, Christina
Stringer-Reasor, Erica
Wei, Shi
Chien, A. Jo
Albain, Kathy S.
Kalinsky, Kevin
Wallace, Anne
Elias, Anthony
Yee, Douglas
Clark, Amy S.
Boughey, Judy C.
Han, Heather
Nanda, Rita
Isaacs, Claudine
Mitri, Zahi
Lang, Julie E.
Thomas, Alexandra
Sanft, Tara
DeMichele, Angela
Perlmutter, Jane
Rugo, Hope S.
Hylton, Nola M.
Symmans, W. Fraser
Melisko, Michelle E.
van't Veer, Laura J.
Wilson, Amy
Asare, Smita M.
Sanil, Ashish
Berry, Donald A.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2021, 81 (04)
[39] Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial.
Mukhtar, R. A.
Lips, E.
Wesseling, J.
Livasy, C.
Yau, C.
Berry, D.
van't Veer, L.
Carey, L. A.
Esserman, L. J.
Rodenhuis, S.
Hwang, E. S.
[J]. CANCER RESEARCH, 2011, 71
[40] The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL
Silverstein, J.
Suleiman, L.
Yau, C.
Price, E. R.
Singhrao, R.
Yee, D.
DeMichele, A.
Isaacs, C.
Albain, K. S.
Chien, A. J.
Forero-Torres, A.
Wallace, A. M.
Pusztai, L.
Ellis, E. D.
Elias, A. D.
Lang, J. E.
Lu, J.
Han, H. S.
Clark, A. S.
Korde, L.
Nanda, R.
Northfelt, D. W.
Khan, Q. J.
Viscusi, R. K.
Euhus, D. M.
Edmiston, K. K.
Chui, S. Y.
Kemmer, K.
Wood, W. C.
Park, J. W.
Liu, M. C.
Olopade, O.
Leyland-Jones, B.
Tripathy, D.
Moulder, S. L.
Rugo, H. S.
Schwab, R.
Lo, S.
Helsten, T.
Beckwith, H.
Berry, D. A.
Asare, S. M.
Esserman, L. J.
Boughey, J. C.
Mukhtar, R. A.
[J]. CANCER RESEARCH, 2019, 79 (04)

← 1 2 3 4 5 →